https://orcid.org/0000-0002-3007-3898
References
- Barros A, Pulido C, Machado M, et al. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). Int J Oncol. 2021;59(6):110. doi: 10.3892/ijo.2021.5290
- Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–1617. doi: 10.1056/NEJMra0901557
- Napolitano F, Formisano L, Giardino A, et al. Neoadjuvant treatment in locally advanced pancreatic cancer (LAPC) patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: a single-center experience and a literature review. Cancers (Basel). 2019;11(7):981. doi: 10.3390/cancers11070981
- Walton M, Wade R, Claxton L, et al. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technol Assess. 2020;24(48):1–264. doi: 10.3310/hta24480
- Filippi L, Di Costanzo GG, Tortora R, et al. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization. Nucl Med Commun. 2020;41(1):78–86. doi: 10.1097/MNM.0000000000001123
- Cheng Y, Kiess AP, Herman JM, et al. Phosphorus-32, a clinically available drug, inhibits cancer growth by inducing DNA double-strand breakage. PLoS One. 2015;10(6):e0128152. doi: 10.1371/journal.pone.0128152
- Gao W, Liu L, Liu Z-Y, et al. Intratumoral injection of 32 P-Chromic phosphate in the treatment of implanted pancreatic carcinoma. Cancer Biother Radiopharm. 2010;25(2):215–224. doi: 10.1089/cbr.2008.0596
- Gao W, Liu L, Teng G-J, et al. Internal radiotherapy using 32P colloid or microsphere for refractory solid tumors. Ann Nucl Med. 2008 Oct;22(8):653–660. doi: 10.1007/s12149-008-0176-6
- Bhutani MS, Cazacu IM, Luzuriaga Chavez AA, et al. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE. 2019;4(5):223–225. doi: 10.1016/j.vgie.2019.02.009
- Bhutani M, Klapman J, Tuli R, et al. An open-label, single-arm pilot study of EUS-guided brachytherapy with phosphorus-32 microparticles in combination with gemcitabine ± nab-paclitaxel in unresectable locally advanced pancreatic cancer (OncoPaC-1): technical details and study protocol. Endosc Ultrasound. 2020;9(1):24–30. doi: 10.4103/eus.eus_44_19
- Bhutani MS, Klapman JB, Tuli R, et al. OncoPaC-1: an open-label, single-arm Pilot study of phosphorus-32 microparticles brachytherapy in combination with gemcitabine ± nab-paclitaxel in unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2019;105(1):E236–E237. doi: 10.1016/j.ijrobp.2019.06.2010
- Ross PJ, Wasan HS, Croagh D, et al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open. 2022;7(1):100356. doi: 10.1016/j.esmoop.2021.100356
- Filippi L, Dimitrakopoulou-Strauss A, Evangelista L, et al. Long axial field-of-view PET/CT devices: are we ready for the technological revolution? Expert Rev Med Devices. 2022;19(10):739–743. doi: 10.1080/17434440.2022.2141111
- Naidu J, Bartholomeusz D, Zobel J, et al. Combined chemotherapy and endoscopic ultrasound-guided intratumoral 32P implantation for locally advanced pancreatic adenocarcinoma: a pilot study. Endoscopy. 2022;54(1):75–80. doi: 10.1055/a-1353-0941